PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

ABPI reacts to new vital vaccination report

A new HSCC document deems the UK’s vaccination position to be at risk.

The Health and Social Care Select Committee has published the broad results of its inquiry into global vaccinations.

The report, entitled Prevention in health and social care: vaccination, notes that the UK’s world-leading role in vaccination is in jeopardy due to a number of ongoing factors.

Indeed, the document insists that without urgent action to address challenges around the general uptake of vaccines and wider bureaucratic processes – particularly in the setting up of clinical trials – the UK’s world-leading position is at risk.

Ben Lucas, managing director at MSD and Association of the British Pharmaceutical Industry (ABPI) board member, delivered evidence to the inquiry on behalf of the ABPI. During his assessment, he highlighted the UK’s impressive record in terms of global vaccination but also underlined the variety of complex challenges.

He said: “The UK has historically had a strong record on vaccination, so it is frustrating to see rates going in the wrong direction when better preventative measures could ease wider pressures on the NHS. To get back on track, we must look at the whole immunisation journey, from development to assessment, through to getting vaccines to those who need them.

“Firstly, we must fix the slow and bureaucratic setup of clinical trials to streamline innovation. Next, we need to ensure our regulators and independent scientific advisers have the resources they need to properly assess new vaccines quickly.”

He added: “Finally, we need the right data and healthcare teams in place to deliver flexible vaccination services tailored to the needs of local communities and underserved populations.”

Ultimately, the ABPI welcomed the Committee’s comprehensive report and said it looked forward to seeing the forthcoming NHS vaccination strategy, which it hoped would put the recommendations into action.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026